Current ADGC Special Analysis Group Projects (SAGs)

#. University/Institute: PI of Special Analysis Project

  • SAG Title
  • SAG Approval Date
  1. Washington University: Alison Goate (PI)
    • Use of biological and evolutionary information to prioritize SNPs from the ADGC genome-wide association studies for follow-up
    • Approved in 2009
  2. Vanderbilt University: Jonathan Haines (PI)
    • Detection of Gene x Gene Interactions in LOAD GWAS Data
    • Approved in 2009
  3. NIA and University College London: John Hardy (PI)
    • Epigenetic and Expression Modifications Associated with AD Risk SNPs
    • Approved in 2009
  4. Mayo Clinic: Nilufer Ertekin-Taner (PI)
    • Analysis of the ADGC GWAS Datasets to Identify Alzheimer’s Disease Susceptibility Factors Influencing Neuropathology Endophenotypes
    • Approved in 2009
  5. University of Kentucky: Peter Nelson (PI)
    • GWAS to identify SNPs associated with pathologically-verified hippocampal sclerosis
    • Approved in 2010
  6. Massachusetts General Hospital and University of Washington: Deborah Blacker (PI)
    • A genome-wide association study of Alzheimer’s disease with psychosis (AD+P)
    • Approved in 2010
  7. Columbia University: Sandra Barral Rodriguez(PI)
    • Identification of mitochondrial DNA variants associated with Alzheimer's disease
    • Approved in 2010
  8. University of Washington, Boston University, and Indiana University: Paul Crane(PI)
    • Psychometrically sophisticated GWAS: Cognitive decline among AD cases in the ADGC
    • Approved in 2010
  9. University of Pennsylvania: Li-San Wang (PI)
    • CNV Analysis of the ADGC Phase 1+2 Dataset
    • Approved December 8, 2009
  10. Mayo Clinic: Nilufer Ertekin-Taner (PI)
    • Analysis of variants in the chromosome 10 VR22/LRRTM3 region in the combined ADGC and Mayo Clinic Dataset
    • Approved August 13, 2010
  11. University of Pennsylvania: Li-San Wang (PI)
    • Pathway and eSNP Analysis of AD and Cognitive decline
    • Approved November 3, 2010
  12. Washington University: Alison Goate (PI)
    • Analysis of ADGC GWAS data for association with cerebrospinal fluid (CSF) biomarkers for LOAD
    • Approved November 3, 2010
  13. Boston University: Badri Vardarajan (PI)
    • Analysis of Gene Interactions for AD Risk Using a Cooperative Game Theory Approach
    • Approved November 12, 2010
  14. New York University: Iryna Lobach (PI)
    • Analysis of Gene-Environment Interactions Involved in AD
    • Approved May 3, 2011
  15. University of Pennsylvania: Neal Sondheimer (PI),
    • Evaluation of Mitochondrial Heteroplasmy in AD GWAS datasets
    • Approved March 1, 2011
  16. ROS/MAP: Philip De Jager (PI)
    • Validation of a CR1 susceptibility allele
    • Approved March 1, 2011
  17. Mayo Clinic: Nilufer Ertekin-Taner (PI)
    • Combined GWAS for brain gene expression levels and AD risk
    • Approved March 1, 2011
  18. Rush University, Harvard: Philip De Jager MD (PI)
    • Replication of Genome-wide Scans for AD-related Intermediate Phenotypes and Functional Validation in Drosophila
    • Approved March 16, 2011
  19. Columbia University: Sandra Barral (PI)
    • Multi-locus genotype patterns associated with episodic memory in the NIA-LOAD/NCRAD Study
    • Approved March 16, 2011
  20. University of Washington: Paul Crane (PI)
    • Pathway-wide association study (PWAS) of AD
    • Approved April 21, 2011
  21. University of Pennsylvania, Lehigh University: Shin-Yi Chou (PI)
    • Alzheimer’s Disease and toxicity exposure: a gene-environment Interactions analysis
    • Approved June 9, 2011
  22. Columbia University: Chistiane Reitz (PI)
    • SORCS2, SORCS3 and SORT1 and risk of Alzheimer’s disease
    • Approved June 9, 2011
  23. Mayo Clinic: Rosa Rademakers (PI)
    • Determine risk associated with TMEM106B SNP rs1990622 in AD
    • Approved June 9, 2011
  24. Mayo Clinic & University of Texas: Nilufer Ertekin-Taner (PI)
    • Joint Analysis of Genomic and Transcriptomic Data to Identify Novel AD Risk Genes
    • Approved June 13, 2011
  25. Oregon Health and Sciences University: Patricia Kramer (PI)
    • Replication of a GWAS for autopsy-confirmed AD cases and controls
    • Approved June 13, 2001
  26. University of Miami & Autopsy-confirmed Parkinson Disease GWAS Consortium (APDGC): Gary Beecham (PI)
    • ADGC Controls for Parkinson Disease GWAS
    • Approved August 26, 2011
  27. Bringham Young University: Keoni Kauwe (PI)
    • Pleiotropy and Interactions in CSF Biomarkers for AD
    • Approved October 4, 2011
  28. Genentech: Timothy Behrens (PI)
    • Whole-genome sequence analysis of early-onset Alzheimer’s disease in APOE 3/4 and 4/4 subjects
    • Approved September 21, 2011
  29. Emory University: Thomas Wingo (PI)
    • The proportion of common SNPs that explain late-onset Alzheimer’s disease
    • Approved November 15, 2011
  30. North American Pancreatic Study Group (NAPS): Bernie Devlin (PI)
    • Genetic risk in recurrent acute and chronic pancreatitis
    • Approved January 30, 2012
  31. Bringham Young University: Keoni Kauwe (PI)
    • Remaining genetic variance in clinical diagnosis of Alzheimer’s disease
    • Approved January 30, 2012
  32. University of California San Francisco: Jennifer Yokoyama (PI)
    • Investigation for genetic loci underlying depressive symptomatology in Alzheimer’s Disease
    • Approved February 10, 2012
  33. University of California Los Angeles & University of Pennsylvania: John Ringman (PI)
    • Analysis of genetic association of dementia and handedness
    • Approved May 11, 2015
  34. University of California San Diego: Rahul Desikan (PI)
    • Leveraging annotation and genetic pleiotropy methods to improve gene discovery in Alzheimer’s disease
    • Approved June 20, 2012
  35. Washington University: Paul Crane (PI)
    • Bayesian genome-wide association study (BGWAS) of Alzheimer’s Disease
    • Approved July 5, 2012
  36. Washington University: Paul Crane (PI)
    • Topic – Comparison of approaches to gene-wide association studies for AD
    • Approved September 19, 2012
  37. Washington University: Paul Crane (PI)
    • Mendelian randomization in the ADGC: obesity and AD risk
    • Approved September 19, 2012
  38. Indiana University: Tatiana Foroud (PI)
    • Identification of rare variants contributing to Parkinson disease: Request for control data
    • Approved October 8, 2012
  39. University of Washington & NACC: Andrew Zhou (PI)
    • Cure-rate Model for Dementia with the combined ADC and UDS
    • Approved February 18, 2013
  40. Pfizer: Hyuna Yang (PI), Eve H Pickering and Jens Wendland
    • Association between lipids (HDL-c, LDL-c, and TG) and AD
    • Approved November 19, 2012
  41. University of Washington: Shubhabrata Mukherjee (PI)
    • Analyses of SNP associations with AD from the combined ADGC data set
    • Approved February 18, 2013
  42. University of Kentucky, University of Washington & Indiana University: David Fardo (PI)
    • Inflammation and Alzheimer’s Disease: A Genome-wide Investigation of Interrelated Pathways
    • Approved February 18, 2013
  43. Columbia University: Christiane Reitz (PI)
    • Interaction between environmental factors and genetic variants in late onset Alzheimer’s disease
    • Approved February 19, 2013
  44. Washington University: Alison Goate (PI)
    • Using CSF biomarker levels to identify potential functional mechanisms of the GWAS hits
    • Approved February 18, 2013
  45. Brigham Young University: John Kauwe (PI)
    • Remaining genetic variance in clinical diagnosis of Alzheimer’s disease
    • Approved February 18, 2013
  46. Mayo Clinic: Nilufer Ertekin-Taner (PI)
    • MAPT haplotype analyses in ADGC dataset
    • Approved February 25, 2013
  47. King’s College London: Angela Hodges (PI)
    • CSF1R and association with late onset Alzheimer’s Disease
    • Approved March 1, 2013
  48. Columbia University: Sandra Barral (PI)
    • Memory performance in ADC/NACC data
    • Approved June 3, 2013
  49. Washington University: Sarah Monsell (PI)
    • Genetic differences between symptomatic and asymptomatic persons with Alzheimer's Disease neuropathologic change
    • Approved June 24, 2013
  50. Stanford University: Michael Grecius (PI)
    • Interaction between APOE and gender in functional imaging biomarkers              
    • Approved October 9, 2013
  51. University of Washington: Paul Crane (PI)
    • Genetics of neuropathologically defined and CSF defined resilience phenotypes
    • Approved September 27, 2013
  52. Columbia University: Joseph Lee (PI)
    • Confirmation of the APOE effector genes using the combined ADGC data set
    • Approved October 9, 2013
  53. Vanderbilt University: Timothy Hohman (PI)
    •  Leveraging biomarker and autopsy measures of pathology to identify novel genetic interactions
    • Approved September 27, 2013
  54. Washington University & Bringham Young University: Alison Goate (PI)
    • Use of censored data to identify genetic modulators of age at onset of AD in the entire ADGC dataset and in subsets stratified by APOE genotype
    • Approved October 23, 2013
  55. Rush University: Philip De Jager (PI)
    • Request for summary statistics of Late-Onset Alzheimer Disease GWAS In Europeans and African Americans
    • Approved September 30, 2013
  56. Columbia University: Guiseppe Tosto (PI)
    • Analysis of genetic susceptibility loci underlying Alzheimer's disease with parkinsonism and hallucinations
    • Approved October 22, 2013
  57. University of Toronto & Columbia University: Ekaterina Rogaeva (PI)
    • Genome-wide survey of runs of homozygosity in African Americans with late-onset Alzheimer Disease
    • Approved October 22, 2013
  58. Washington University: Alison Goate (PI)
    • Analysis of ADGC GWAS data for association with CSF biomarkers for LOAD
    • Approved November 22, 2013
  59. Columbia University: Christiane Reitz (PI)
    • Re-Analysis of IGAP Mega-Meta loci and Sortilin pathway genes in African Americans
    • Approved November 30, 2013
  60. Columbia University: Sandra Barral (PI)
    • Dentate Gyrus differential expressed genes and memory performance in ADGC data
    • Approved December 11, 2013
  61. University of Pennsylvania: Li-San Wang (PI)
    • Mendelian randomization analysis of the relationship between depression and Alzheimer’s disease
    • Approved December 11, 2013
  62. Boston University: Jesse Mez (PI)
    • A liability model to increase power in genome-wide association
    • Approved January 22, 2014
  63. University of Washington, Massachusetts General Hospital & Columbia University – Debby Tsuang (PI)
    • Interaction of TAU haplotypes and Head Injury in conferring risk of Alzheimer’s disease
    • Approved January 27, 2014
  64. University of Kentucky: David Fardo (PI)
    • Replication and Exploration of Alzheimer’s Disease Epistasis Signals
    • Approved February 26, 2014
  65. Columbia University: Christiane Reitz (PI)
    • Using GWAS results to identify the types of functional genomic information most relevant for interpreting loci that influence Alzheimer’s disease
    • Approved May 20, 2014
  66. University of Washington: Joey Mukherjee (PI)
    • A systems-biology approach to identify candidate genes for Alzheimer’s Disease by integrating protein-protein interaction network and subsequent in vivo validation of candidate genes using a C. elegans model of Aβ toxicity
    • Approved July 22, 2014
  67. University of California San Diego: Rahul Desikan (PI)
    • Leveraging genetic overlap to detect novel Alzheimer’s disease susceptibility loci
    • Approved September 26, 2014
  68. University of Washington: Joey Mukherjee (PI)
    • Conditional and joint multiple-SNP analysis of GWAS summary statistics from the IGAP 1000 genomes-imputed meta-analysis
    • Approved November 10, 2014
  69. Boston University: Yiyi Ma (PI)
    • Investigation of the Association of CpG-related SNPs (CGSs) with AD
    • Approved December 8, 2014
  70. University of Miami: Brian Kunkle (PI)
    • Association Analysis of ABCA7 deletion in ADGC African American GWAS Datasets
    • Approved December 22, 2014
  71. Children’s Hospital of Philadelphia: Hakon Hakonarson (PI)
    • The role of vitamin D in prevention of cognitive decline in Alzheimer’s Disease: a Mendelian Randomization study
    • Approved March 9, 2015
  72. University of California San Diego: Chi-Hua Chen (PI)
    • Identifying Polygenic Basis of the Human Brain and Brain Disorders
    • Approved March 9, 2015
  73. University of Pennsylvania: Mitchell Tang (PI)
    • Evaluating a Potential Independent Association with AD at ABCA7
    • Approved March 9, 2015
  74. Children’s Hospital of Philadelphia: Hakon Hakonarson (PI)
    • Comparative analysis of the sex specific association results for AD against results for fronto-temporal dementia (FTD) to identify shared loci / pathways
    • Approved May 21, 2015
  75. University of Southern California: Kaida Ning (PI)
    • Pathways, effect of genetic interaction on age of onset, ventricular dilation rate and amyloid-β level, and AD risk prediction
    • Approved August 24, 2015
  76. Vanderbilt University: Tim Hohman (PI)
    • Disentangling the Association between Genetic Ancestry and Socioeconomic Status
    • Approved August 21, 2015
  77. TGen: Matthew Huentelman (PI)
    • Disease association analysis of variants with differential effects dependent on APOE status
    • Approved August 20, 2015
  78. University of Washington: Joey Mukherjee (PI)
    • Conditional and joint multiple-SNP analysis of GWAS summary statistics from the ADGC neuropathological analysis
    • Approved September 4, 2015
  79. University of Washington: Joey Mukherjee (PI)
    • Post-GWAS prioritization of Alzheimer’s disease loci bsd on genomic functional annotation
    • Approved September 4, 2015
  80. University of Pennsylvania: John Toledo (PI)
    • Comorbid Lewy Body Dementia among AD cases in the ADGC
    • Approved November 23, 2015
  81. Boston University: Jaeyoon Chung (PI)
    • Multivariate phenotypes association study of neuropathological features of Alzheimer’s disease and related dementias
    • Approved September 28, 2015
  82. University of Pennsylvania: David Irwin (PI)
    • Genetic Influence and Clinical Expression of Tauopathy across AD/FTD
    • Approved December 1, 2015
  83. University of California San Diego: Nicholas Schork (PI)
    • Application of Novel Methods for Accommodating Heterogeneity
    • Approved December 4, 2015
  84. Columbia University: Julia Ciampa (PI)
    • Identification of endocytosis-related variants associated with entorhinal cortex volume in AD
    • Approved January 11, 2016
  85. University of Southern California: Priya Bhatt (PI)
    • The relationship of the KL-VS variants to phenotypic traits of Alzheimer’s disease in humans
    • Approved February 24, 2016
  86. Yale University & University of Washington: Hongyu Zhao (PI)
    • Improving genetic risk prediction for Alzheimer's disease through integrating genomic functional annotation
    • Approved April 14, 2016
  87. University of California San Francisco: Jennifer Yokoyama (PI)
    • Investigation of HLA contributions to risk for Alzheimer’s Disease
    • Approved June 20, 2016
  88. Case Western University: Will Bush (PI)
    • Nuclear-Mitochondrial Interactions that Influence Neurocognitive Impairment
    • Approved July 11, 2016
  89. Columbia University: Sandra Barral (PI)
    • Genetic Variation Underlying Traumatic Brain Injury and Late-Onset Alzheimer's Disease
    • Approved August 22, 2016
  90. University of Pennsylvania & University of Texas Health Science Center: Piper Below (PI)
    • Tissue-specific analysis of genetically-regulated expression in Alzheimer's Disease (AD)
    • Approved August 22, 2016
  91. University of Miami: Brian Kunkle (PI)
    • IGAP rare-variant GWAS Pathway analysis proposal
    • Approved August 31, 2016
  92. Boston University: Dan Lancour (PI)
    • Identifying Functional AD Genes by Integrating Large-Scale eQTL and Alzheimer’s Disease Genetic Association Data
    • Approved September 19, 2016
  93. Boston University: Yiyi Ma (PI)
    • Age Stratified Analysis
    • Approved September 19, 2016
  94. Vanderbilt University: Timothy Hohman (PI)
    • Sex-specific drivers of Alzheimer’s Disease
    • Approved September 19, 2016
  95. Boston University & University of Washington: Rick Sherva (PI)
    • Genetics of Rate of Cognitive Decline in AD Cases
    • Approved September 19, 2016
  96. Boston University: Jaeyoon Chung (PI)
    • Evaluation of Pleiotropy between Cancer and Alzheimer Disease as a Means to Detect Novel AD Susceptibility Loci
    • Approved September 19, 2016
  97. University of Pennsylvania: Weixin Wang (PI)
    •  Analysis of common and rare variants in progressive supranuclear palsy using ADGC controls
    • Approved November 18, 2016
  98. University of Pennsylvania: Alex Amlie-Wolf (PI)
    • Computational analysis of regulatory effects of IGAP-identified noncoding genetic variants
    • Approved November 18, 2016
  99. Case Western Reserve University: Will Bush (PI)
    • Loss of the Y chromosome in Alzheimer’s Disease
    • Approved March 6, 2017
  100. Boston University: Xiaolin Zhang (PI)
    • Identification of mitochondrial variants associated with late-onset Alzheimer’s disease
    • Approved March 6, 2017
  101. Indiana University: Kwangsik Nho (PI)
    • Apolipoprotein E gene polymorphism and Alzheimer’s disease in different populations
    • Approved May 16, 2017
  102. Indiana University: Miyeon Jung (PI)
    • Testing a Model of Cognitive Function with APOE and BDNF Genes and Heart Failure among Persons with Normal Cognition, MCI, and AD
    • Approved April 24, 2017
  103. Columbia University: Giuseppe Tosto (PI)
    • Epistasis in late-onset Alzheimer’s disease
    • Approved April 24, 2017
  104. University of Washington: Paul Crane (PI)
    • Higher density imputation panel samples for the EPAD project
    • Approved July 3, 2017
  105. University of California San Diego: Rahul Desikan (PI)
    • Cross-Ethnic prediction on the age-at-onset of Alzheimer’s disease with polygenic hazard scores
    • Approved August 14, 2017
  106. University of Pennsylvania, Columbia University: Rhea Bhatta (PI)
    • Analysis of Gene-Environment Interactions in Alzheimer’s Disease:  Education and Intelligence
    • Approved August 14, 2017
  107. University of Miami: Brian Kunkle (PI)
    • Sex-specific Analysis of the ADSP Case-control and ADGC Datasets
    • Approved August 14, 2017
  108. University of Washington & Yale University: Shubhabrata Mukherjee (PI)
    • Gene-level association mapping for late-onset Alzheimer’s disease through cross-tissue imputation of gene expression
    • Approved October 2, 2017
  109. University of Washington: Chang-En Yu (PI)
    • Analysis of TOMM40 gene promoter haplotype in Alzheimer’s disease
    • Approved October 2, 2017
  110. Boston University: John Farrell (PI)
    • Disease Specific Imputation Panel for Testing Association of Late-Onset Alzheimer Disease
    • Approved September 14, 2017
  111. University of Miami: Brian Kunkle (PI)
    • ADGC African American Haplotype Reference Consortium Genome-wide Association Study
    • Approved October 12, 2017
  112. University of Pittsburgh: Robert Sweet (PI)
    • Alzheimer’s Disease + Psychosis
    • Approved October 12, 2017
  113. University of Kentucky: David Fardo (PI)
    • Examining AD-related endophenotypes, partitioned genetic covariance, and cognitive decline
    • Approved October 31, 2017
  114. University of Kentucky: David Fardo (PI)
    • Exploration of Alzheimer's Disease SNPs and Candidate Causal Proxies
    • Approved November 9, 2017
  115. Mayo Clinic Jacksonville: Nilufer Ertekin-Taner (PI)
    • Meta-analyses of ADGC African American GWAS and Mayo AA WES datasets
    • Approved December 22, 2017
  116. Icahn School of Medicine at Mount Sinai: Alison Goate (PI)
    • Discovery of Rare Variation and Non-Alzheimer’s Phenotypes Associated with Polygenic AD Risk
    • Approved January 5, 2018
  117. Massachusetts General Hospital: Jaeyoon Chung (PI)
    • Genetic association between Alzheimer’s disease and cerebral small/large vessel diseases in subgroups stratified by APOE genotypes
    • Approved May 9, 2018
  118. Washington University: Carlos Cruchaga (PI)
    • Identification of the genetic architecture common to Alzheimer’s disease risk and rate of progression
    • Approved March 30, 2018
  119. University of California San Diego: Chi-Hua Chen (PI)
    • Identification of Genetic Heterogeneity of Alzheimer’s Disease (AD) by Age, Sex, and APOE Status
    • Approved May 9, 2018
  120. University of Miami: Eden Martin (PI)
    • Sex-specific Analysis of the ADGC AND IGAP Datasets
    • Approved May 2, 2018
  121. University of California San Francisco: Jennifer Yokoyama (PI)
    • Post-GWAS protein interaction network analysis to identify novel biological processes in Alzheimer’s disease
    • Approved May 2, 2018
  122. Icahn School of Medicine at Mount Sinai & University of Pennsylvania: Alan Renton (PI)
    • APOE ε4 and ε3/ε3 Extremes Meta-analysis using ADGC HRC-Imputed data with ADSP sequence data
    • Approved May 23, 2018
  123. University of Washington: Shubhabrata Mukherjee (PI)
    • Genetically-informed association analysis tests associations between risk factors and late-onset Alzheimer’s disease
    • Approved August 6, 2018
  124. University of California San Francisco: Rahul Desikan (PI)
    • Cardiovascular mediated polygenic enrichment in Alzheimer’s disease
    • Approved August 6, 2018
  125. University of Miami: Eden Martin (PI)
    • Genetic Basis for Age-at-Onset of AD
    • Approved August 6, 2018
  126. University of Pennsylvania: Fanny Leung (PI)
    • Studying the regulatory effects of population-specific noncoding genetic variants identified in AD GWAS studies
    • Approved October 17, 2018
  127. Boston University: Gyungah Jun (PI)
    • Comprehensive assessment for effect sizes of APOE genotypes for Alzheimer’s disease risk and neuropathological traits
    • Approved January 23, 2019
  128. University of Pennsylvania: Corey McMillan (PI)
    • PART Analysis
    • Approved March 23, 2019
  129. Icahn School of Medicine at Mount Sinai: Thomas Zhang (PI)
    • Identify and genotype copy number variants (CNVs) and perform CNV based GWAS and eQTL analyses for Alzheimer’s Disease
    • Approved June 3, 2019
  130. Munich University & Mayo Clinic: Gunter Höglinger (PI)
    • MSA GWAS
    • Approved April 28, 2019
  131. Massachusetts General Hospital: Sudeshna Das (PI)
    • Understanding the Protective Effect of an APOE ε4-linked haplotype using Integrative Bioinformatics Analysis
    • Approved June 13, 2019
  132. Munich University & University of California San Diego: Simon Larsen (PI)
    • Analysis of genetic variants in Alzheimer’s disease using a hierarchical model of the cell
    • Approved May 15, 2019
  133. VAI & University of Pennsylvania: Jose Bras (PI)
    • Lewy Body Dementia Genetics
    • Approved June 13, 2019
  134. Boston University: Gyungah Jun (PI)
    • APOE Stratified Polygenic Risk Score Analysis using Machine Learning and Mendelian Randomization Approach
    • Approved September 27, 2019
  135. University of Miami: Peggy Pericak-Vance (PI)
    • Estimating Bias-free Polygenic Risk Scores for Alzheimer Disease in Admixed Populations
    • Approved September 17, 2019
  136. Boston University: Jaeyoon Chung (PI)
    • Genetic Association Studies for Identifying Novel AD Risk Factors Using Polygenic Structure of Cerebral Small Vessel Disease
    • Approved August 28, 2019
  137. University of Pennsylvania: Iain Mathieson (PI)
    • Nonlinear Risk Prediction for Alzheimer’s Disease with Convolutional Neural Networks
    • Approved March 6, 2020
  138. University of Miami: Gary Beecham (PI)
    • Shared Heritability of Early-Onset AD with Late-Onset AD and Age of Onset
    • Approved February 28, 2020
  139. University of Miami: Gary Beecham (PI)
    • Shared Heritability of Early-Onset AD with Vascular Traits and Depression
    • Approved February 28, 2020
  140. Cleveland Clinic: Jagan Piallai (PI)
    • Vesicular transport related genes and age of onset in Alzheimer’s disease
    • Approved April 2, 2020
  141. Icahn School of Medicine at Mount Sinai: Shea Andrews (PI)
    • Assessing the causal role of mitochondria in Alzheimer’s disease
    • Approved May 15, 2020
  142. University of Pennsylvania: Thomas Tropea (PI)
    • External Validation Cohort for a Clinical-genetic Predictor of Co-ccurring AD Pathology in Primary Lewy Body Disease (LBD) Cases
    • Approved June 8, 2020
  143. Case Western Reserve University: Jonathan Haines (PI)
    • Rapid Decline in AD
    • Approved July 17, 2020

 

Updated on August 18th, 2020